Delaware District Court Grants Bio-Rad’s Motion for Permanent Injunction Against 10X Genomics
July 24 2019 - 9:52PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products,
announces that today the Delaware District Court granted Bio-Rad’s
motion for permanent injunction against 10X Genomics from making
any sales of infringing products to new customers and granting
Bio-Rad’s request for supplemental damages and pre- and
post-judgement interest. The court also acknowledged Bio-Rad’s
agreement to allow 10X to continue to sell consumables for use with
already sold systems, subject to payment of a royalty.
Today’s decision follows the Court’s decision earlier this month
affirming the unanimous finding of a jury that 10X Genomics
willfully infringed three United States Patents owned by the
University of Chicago and exclusively licensed to Bio-Rad
Laboratories, Inc. On November 13, 2018, a Delaware jury found all
three patents valid and infringed, that 10X’s infringement was
willful, and that Plaintiffs were entitled to $23.9 million in
damages. 10X Genomics sought to have the jury’s verdict overturned,
but on July 9, 2019, the judge denied 10X’s motions and issued his
decision upholding the jury verdict, ruling the jury’s unanimous
decision finding 10X had willfully infringed three patents was
“supported by substantial evidence.” In awarding Bio-Rad $23.9
million in damages, the jury unanimously found that all Single Cell
and Linked-Read Genomics products sold by 10X Genomics infringed
the patents.
“We are obviously pleased with the Court’s decisions, upholding
the jury’s award of damages and vindicating our patent rights by
granting an injunction,” said Norman Schwartz, Bio-Rad President
and Chief Executive Officer.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.2 billion in 2018. For more information,
please visit www.bio-rad.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190724005938/en/
Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications
510-724-7000 tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024